Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma
Completed
Subjects who qualify for participation will receive lenalidomide with or without dexamethasone in 4 week cycles until disease progression is documented or lenalidomide becomes commercially available for the indication of multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2010
Locations: University of Texas Southwestern Medical Center, Dallas, Texas +1 locations
Conditions: Multiple Myeloma
Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery
Completed
To demonstrate that the combination formulation of Moxifloxacin/Dexamethasone Eye Drop is effective and safe for the prevention of postoperative inflammation as a consequence of cataract extraction surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2010
Locations: Alcon Call Center, Fort Worth, Texas
Conditions: Cataract
TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension
Completed
The purpose of this study is to describe the differences in efficacy between TOBRADEX Ophthalmic Suspension and Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension in the treatment of ocular inflammation and infection associated with blepharaconjunctivitis
Gender:
ALL
Ages:
2 years and above
Trial Updated:
02/23/2010
Locations: Houston, Houston, Texas
Conditions: Ocular Inflammation Associated With Blepharaconjunctivitis
Tobramycin Tear Concentrations
Completed
To evaluate the Tobramycin tear concentration values of TOBRADEX® Ophthalmic Suspension, Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension versus TOBREX® Ophthalmic Solution in normal volunteers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/23/2010
Locations: Contact Alcon Call Center For Trial Locations, Fort Worth, Texas
Conditions: Dry Eye
A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Terminated
To evaluate the safety and efficacy of lenalidomide (Revlimid ®) in combination with dexamethasone in subjects with relapsed or refractory diffuse large B-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/27/2009
Locations: SouthWest Regional Cancer Center, Austin, Texas
Conditions: Diffuse Large B-cell Lymphoma
Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma
Unknown
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Thalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. Giving bortezomib together with cyclophosphamide, dexamethasone, and thalidomide may kill more cancer cell... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2009
Locations: Lone Star Oncology - Austin, Austin, Texas
Conditions: Multiple Myeloma and Plasma Cell Neoplasm